Our Team

We are driven by giving back.


Board Member, Chair of the Board

Lorna has enjoyed a successful 25-year career in the pharmaceutical industry, encompassing clinical research, business development, marketing, and sales, all across a wide variety of therapeutic areas, including Respiratory, CNS, Cardiopulmonary, Metabolic, Psychiatry, Neurology, HIV, and Vaccines. She has worked in the United States, Europe, and Asia Pacific. She immigrated to Australia in 2002 and worked for GSK Australia as the Commercial Vice President for 5 years. In 2009, she established Ikaria Australia Ltd Pty., a biotherapeutics company that commercialises drugs and devices for intensive care medicine. Lorna is currently Vice President, Commercial Operations of bioCSL Ltd. Lorna graduated with a PhD in Neurobiology (University College London), BSc in Pharmacology (University of Glasgow), and went on to hold academic positions at the Cardiothoracic Institute at the Royal Brompton Hospital (London) and at the Royal Post Graduate Medical School (London).

Founder, Managing Director, and Board Member

Founder and Managing Director of Medicines Development, a biopharmaceutical company focussing on developing and delivering medicines for diseases of low and middle income countries. Key career highlights include 11 years executive management, Advisory Board, and Board of Directors experience in biotechnology and 28 years experience in clinical development within biotechnology, large pharmaceutical, contract services, and academic sectors. Drug development experience encompasses project leadership of 5 products, including moxidectin for the treatment of onchocerciasis, and extensive practical experience of implementation of clinical first exposure, proof of concept, phase 2, global phase 3, phase 3b design and implementation, and phase 4 clinical studies. Significant contributor to 3 successful global registrational programs. Chief Operating Officer of Australia’s HIV vaccine design and development consortium responsible for designing, constructing, manufacturing and clinically evaluating a novel HIV vaccine. Extensive international experience having worked in operating company (UK 4 years), international head office (UK 6 years, US 2 years), contract research (Australia 1 year), and academic settings (Australia 3 years) with direct experience of drug development in 24 countries.

Board Member

Andrew Wilks, BSc, PhD, was most recently Chief Scientific Officer and founder of Cytopia. Prior to starting Cytopia, Andrew was at the Ludwig Institute for Cancer Research in Melbourne where he discovered the JAK kinases. He holds an Honorary Professorship at Monash University (Melbourne) and was the inaugural winner of the Australian Biobusiness Award in 2007. Based in Melbourne, Australia, Andrew co-founded SYN|thesis in 2007 and now oversees global operations.

Board Member

Richard has over 25 years’ experience in negotiating and documenting commercial arrangements and is highly regarded for his expertise in advising clients on all aspects of commercial transactions and corporate issues. Richard was a founding partner of the Banki Haddock Fiora partnership in 1995. His clients include research organisations and universities, statutory corporations, educators, primary industry bodies, publishers, and media operators.

In Memoriam

Board Member

David Cooper, BSc (Med), MBBS (Syd), MD, DSc (UNSW), FRACP, FRCPA, FRCP, FAA (19 April 1949 – 18 March 2018) was Scientia Professor and Director of the Kirby Institute. David was a founding Board member, a member of the company, and friend who will be greatly missed. Vale David Cooper.


Executive Team

Senior Director

In 2005 Amanda joined Medicines Development where she led the development of a therapeutic vaccine for HIV and is currently working on a low cost birth-dose oral rotavirus vaccine. Amanda has 15 years local and international experience in HIV immunology and new product research and development. Amanda completed a Masters in Public Health before joining Bavarian Nordic GmbH in Denmark and Germany with experience gained in preclinical, Phase I and II, smallpox, and viral vector vaccine development. Her responsibilities included managing the clinical analysis group and participation in product development teams.

Associate Director

Following 10 years in research and fellowships with Australia’s leading Universities, Danielle joined Medicines Development for Global Health in 2008. Initially utilising her research experience to advance Medicines Development’s early stage development programs, in her 10 years with the company, she has now managed programs through all stages of development through to registration and commercial outcomes. Her contribution to MDGH programs commonly encompasses a wide scope of responsibilities, including strategic input, operational leadership, risk identification/mitigation, stakeholder management, global program communications, resourcing and project management. Danielle is a graduate of Monash University and has a PhD in immunology from the University of Melbourne.

Senior Director

John joined Medicines Development in 2016 to add his commercial experience as well as his vast experience working over the entire spectrum of drug discovery and development. John’s former positions include Vice President Drug Development and Director, Drug Discovery at Biota Pharmaceuticals. Prior to moving to industry in 2002, John was a Senior Lecturer at the University of Melbourne, an ARC QEII Fellow at the Australian National University, and a post-doctoral fellow at Harvard University. John holds a first-class Honours degree in Science, a PhD in organic chemistry from the University of Melbourne, and is a Graduate of the Australian Institute of Company Directors.

Vice President

Larry joined Medicines Development in 2012 as a highly experienced biotechnology executive with broad R&D, product development, operational, and general management experience, including manufacturing, preclinical and clinical development, and regulatory affairs. He has direct experience in the development of therapeutic vaccines for HIV, HBV, and cancer targets. He has more than 14 years experience in the biotechnology industry at companies including AMRAD and Virax in positions spanning from Laboratory Director to CEO. Larry’s medical research experience is drawn from more than 10 years as a senior medical researcher in leading Australian and international institutes.

Vice President

Sally joined Medicines Development in 2013 with 12 years clinical pharmacy and more than 20 years industry and management experience including 11 years in clinical research and operations, 2 years in commercial, and 6 years in medical affairs at GlaxoSmithKline Australia. Three years as an independent industry consultant focused on clinical operations and scientific writing for industry, research, and government clients. Prior to joining Medicines Development, Chief Operating Officer at Phosphagenics Limited, a publicly listed Australian biotechnology company with development projects in Phases I and II.